

****Updated April 2017****

MarketVIEW: *Acinetobacter baumannii* vaccines (CAT: VAMV070)

Product Name	:	MarketVIEW: <i>Acinetobacter baumannii</i> vaccines
Description	:	Vaccine commercial opportunity assessment
Contents	:	Executive presentation (.pdf) + 1 commercial forecast model(s) (.xls)
Therapeutic Area	:	Nosocomial (hospital) vaccines
Publication date	:	April 2017
Catalogue No	:	VAMV070

Background

Acinetobacter baumannii of the *Acinetobacter spp* is a ubiquitous aerobic gram-negative bacillus which preferentially colonizes aquatic environments. Recently, the bacterium has become a “Priority No 1” pathogen primarily associated with hospital-acquired infections (HAIs). Patients usually affected are those critically ill having been admitted to the intensive care unit (ICU) and often receiving mechanical ventilation. In these instances *A.baumannii* related pneumonia can have high mortality rates of 50% or above. *A.baumannii* hospital infections can be difficult to treat with current antibiotics especially multidrug resistant forms MDR, XDR and PDR. In addition, such infections dramatically increase hospital length of stay (LOS) and economic cost.

There are many drivers to justify the search for new management techniques to *A.baumannii* infections. The development of a prophylactic vaccine is one plausible option especially in light of industry major player efforts directed to *Staphylococcus aureus* and *Clostridium difficile* (C.diff) vaccines.

This **MarketVIEW** product is composed of a comprehensive MS Excel-based model + summary presentation (.pdf) that forecasts the potential commercial value of *Acinetobacter baumannii* vaccines across major Western markets to 2030. Three scenarios (**LO, BASE and HI**) are included based upon successive targeting of patient groups who would benefit from vaccination. A detailed review of disease background and epidemiology is included along with current treatment, unmet needs and rationale for vaccine approach. An ideal **Target Product Profile (TPP)** is defined along with commercial model assumptions with economic pricing justification.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to hospital (nosocomial) vaccines and novel approaches. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of bacterial/nosocomial vaccines has also been utilised.

PRODUCT CONTENTS:

Published October 2016 (CAT No: VAMV070)

****This product is composed of [one forecast model \(.xls\)](#)¹ and [a summary presentation \(.pdf\)](#)²

Contents

Author's note

Executive summary

Key commercial model outputs

A. baumannii vaccine - potential revenues per scenario to 2030

A. baumannii vaccine - potential volumes per scenario to 2030

A. baumannii vaccine - potential revenues per country to 2030 (base)

A. baumannii vaccine - potential volumes per country to 2030 (base)

A. baumannii vaccine - addressable patients (000s) 2020, US

A. baumannii vaccine - price versus efficacy curve

Acinetobacter baumannii - disease background

Acinetobacter baumannii - the pathogen

Colonization rates of *Acinetobacter baumannii*

A. baumannii - infection types

Risk factors for *A. baumannii* infections and/or colonizations

A. baumannii - transmission

Multi drug resistant (MDR) *A. baumannii*

Multi drug resistant (MDR) *A. baumannii* – exacerbating factors

MDR *A. baumannii* - global outbreaks

A. baumannii - main patient populations and settings

A. baumannii - hospital (ICU setting)

A. baumannii - hospital (ICU setting), by infection site

A. baumannii - hospital (ICU setting), risk factors

A. baumannii - hospital (non-ICU setting)

Distribution of *A. baumannii* isolates by hospital ward, Mexico 2000-2011¹

Surgical patients and *A. baumannii* infection

A. baumannii - trauma/disaster/conflict setting

A. baumannii - community setting

Acinetobacter baumannii - epidemiology

A. baumannii - key numbers

A. baumannii - global epidemiology (overview)

¹ Model contents available upon request

² Presentation titles may apply to more than one slide

Continued.....

A. baumannii epidemiology: NNIS (1996-2003), US
% *Acinetobacter* species per ICU infection type 1975-2003
A. baumannii - global prevalence (EPIC II study)
Multi drug resistant (MDR) *A.baumannii* – prevalence
Carbapenem resistant *Acinetobacter* - MYSTIC, 2004¹
(MDR) *A.baumannii* - mortality rate, mean length of stay
Incidence density of carbapenem-resistant AB, Italy 2008-13¹
A.baumannii infection - trends and dynamics
Reasons for increased *A.baumannii* infection
Economic burden
Comparative economic cost with other hospital pathogens
United Nations - General Assembly, September 2016
Acinetobacter baumannii - current treatment and management
Drug resistant *Acinetobacter* and therapeutic options
Antibiotic selection
Treatment of *A.baumannii* infection - novel approaches*
Acinetobacter baumannii vaccine - summary/rational for vaccine development
A. baumannii vaccine development - overview
A. baumannii vaccine development - antigen selection
List of *A. baumannii* surface-exposed or secreted antigens
Promising immunogens for an *A. baumannii* vaccine
A. baumannii vaccine: ideal composition
A. baumannii vaccine development - competitive landscape
Alopexx Pipeline, PNAG (AV0328)
Vaxdyn, VXD-001 profile
Vaxdyn, VXD-001 – future planning
A. baumannii - therapeutic vaccination
Acinetobacter baumannii vaccine - Modelling commercial potential
Target patient populations and role of an *A. baumannii* vaccine
A. baumannii vaccine: target product profile (TPP)
Case study: Valneva AG - IC43-201 Phase II Study
How could a *A.baumannii* vaccine be used in the ICU?
Vaccination to prevent *A.baumannii* CAP (HI SCENARIO)
A. baumannii vaccine forecast model: methodology
A. baumannii vaccine forecast model: general assumptions
Forecast vaccine population flow (base case)
Detailed commercial model assumptions (base case)
Detailed commercial model assumptions (high and low case)
Summary of commercial model scenarios
Summary of vaccine coverage rates applied
High-level pharmacoeconomic analysis: ICU-VAP
US economic burden of VAP and potential cost savings
Risks and challenges
Model caveats and limitations
Bibliography
Disclaimer
About **VacZine Analytics**

Slide number = 89

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$10,995.00**/ GBP **£9000.00**# (Region license)*

Indicative company rate only. Prevailing rate applied to date of transaction.

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total
Agency/consultancy rates (commercial use) are available upon request

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. Cunha, B.A (2016) Acinetobacter. Medscape article. Available at: <http://emedicine.medscape.com/article/236891-overview>. Accessed July 2016
2. Howard A. et al (2012) Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 3(3). 243-250
3. Sunenshine RH et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13: 97-103
4. C. Zeana et al. The epidemiology of multidrug-resistant Acinetobacter baumannii: does the community represent a reservoir? Infect Control Hosp Epidemiol, 24 (2003), pp. 275–279
5. M.E. Griffith et al. Acinetobacter skin colonization of US Army soldiers Infect Control Hosp Epidemiol, 27 (2006), pp. 659–661
6. Bouvresse et al. No evidence of Bartonella quintana but detection of Acinetobacter baumannii in head lice from elementary schoolchildren in Paris Comp Immunol Microbiol Infect Dis, 34 (2011), pp. 475–477
7. Y.W. Chu, C.M. Leung, A.T. Houang, K.C. Ng, C.B. Leung, H.Y. Leung, et al. Skin carriage of Acinetobacter in Hong Kong J Clin Microbiol, 37 (1999), pp. 2962–2967
8. Garcia-Quintanilla M et al (2013) First steps towards a vaccine against Acinetobacter baumannii. [Curr Pharm Biotechnol](#). 14(10):897-902;
9. Ntobeko B et al. ICU-Associated Acinetobacter baumannii Colonisation/Infection in a High HIV-Prevalence Resource-Poor Setting. PLoS ONE 7(12): e52452. doi:10.1371/journal.pone.0052452
10. Corbella X et al. Relevance of Digestive Tract Colonization in the Epidemiology of Nosocomial Infections Due to Multiresistant Acinetobacter baumannii. Clin Infect Dis (1996) 23 (2): 329-334
11. US Centers For Disease Control and Prevention. Acinetobacter in Healthcare Settings. Available at: <https://www.cdc.gov/HAI/organisms/acinetobacter.html>. Accessed October 2016
12. Fournier PE et al. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006 Mar 1; 42 (5): 692-9
13. Weingarten CM et al Evaluation of *Acinetobacter baumannii* infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital. Pharmacotherapy. 1999;19(9):1080–1085
14. Rodríguez-Baño J et al. Long-term control of hospital-wide, endemic multidrug-resistant *Acinetobacter baumannii* through a comprehensive “bundle” approach. Am J Infect Control. 2009;37(9):715–722
15. Garcia-Garmendia J-L et al Mortality and the increase in length of stay attributable to the acquisition of *Acinetobacter* in critically ill patients. Crit Care Med. 1999;27(9):1794–1799.
16. Maragakis L & Perl T (2008) *Acinetobacter baumannii*: Epidemiology, Antimicrobial Resistance, and Treatment Options. Clin Infect Dis. 46 (8):1254-1263
17. Falagas M.E & Karveli E.A (2007) The changing global epidemiology of *Acinetobacter baumannii* infections: a development with major public health implications. Clinical Microbiology and Infection. Volume 13, Issue 2, 117-119
18. Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994; 344:1329-32
19. Chastre J. Infections due to Acinetobacter baumannii in the ICU. Semin Resp Crit Care Med 2003;24:69- 78.
20. Durante-Mangoni E et al. Global spread of drug resistant Acinetobacter baumannii. Future Microbiology. 2011;6(4):407-422
21. Peleg et al (2008) Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin Microbiol Rev. 2008 Jul; 21(3): 538–582
22. Ruppe E et al. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Am Intensive Care. 2015; 5:21
23. Bassetti M et al (2008) Drug treatment for multi-drug resistant *Acinetobacter baumannii* infections. Future Microbiology. 3(6) 649-660
24. del Mar Tomas M, Cartelle M, Pertega S, Beceiro A, Llinares P, et al. (2005) Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk factors for colonisation and infection. Clin Microbiol Infect 11: 540–546. doi: 10.1111/j.1469-0691.2005.01184.x
25. Katsaragakis S et al. *Acinetobacter baumannii* Infections in a Surgical Intensive Care Unit: Predictors of Multi-drug Resistance. World J Surg (2008) 32: 1194.
26. He L et al [Multidrug-resistant Acinetobacter Baumannii infection in Intensive Care Unit: A retrospective analysis]. Abstract 2015 Dec;40(12):1327-32.
27. Ntobeko B et al. ICU-Associated Acinetobacter baumannii Colonisation/Infection in a High HIV-Prevalence Resource-Poor Setting. PLoS ONE 7(12): e52452. doi:10.1371/journal.pone.0052452
28. Andres MA et al. DIFFERENCES IN ACINETOBACTER BAUMANNII INFECTION ACCORDING TO ADMISSION PLACE: INTENSIVE CARE UNIT OR MEDICAL/SURGICAL WARD. ESCMID Poster.
- 29.

30. Otero MO et al. *Acinetobacter baumannii* Infections in a Tertiary Care Hospital in Mexico over the Past 13 Years. *Chemotherapy* 2013;59:57-65
31. Garmendia et al. Risk Factors for *Acinetobacter baumannii* Nosocomial Bacteremia in Critically Ill Patients: A Cohort Study. *Clin Infect Dis.* 33 (7); 939-946
32. Sieniawski K et al. *Acinetobacter baumannii* nosocomial infections. [Pol Przegl Chir.](#) 2013 Sep;85(9):483-90. doi: 10.2478/pjs-2013-0075
33. Otero MO et al. *Acinetobacter baumannii* Infections in a Tertiary Care Hospital in Mexico over the Past 13 Years. *Chemotherapy* 2013;59:57-65
34. Delgado-Rodriguez M et al. Nosocomial infection, indices of intrinsic infection risk, and in-hospital mortality in general surgery. *J Hosp Infect* 1999;41:203e11
35. Chen SJ et al. Predictors of mortality in surgical patients with *Acinetobacter baumannii* bacteremia. *Journal of Microbiology, Immunology and Infection* (2011) 44, 209e214
36. Y. Wang, P. Hao, B. Lu, H. Yu, W. Huang, H. Hongliang, K. Dai Causes of infection after earthquake, China, 2008 *Emerg Infect Dis*, 16 (2010), pp. 974–975
37. Kanafani ZA, Kanj SS. Microbiology, pathogenesis and epidemiology of *Acinetobacter* infection. In: Basow DS, editor. *UpToDate*. Waltham, MA, 2010
38. G.L. Goodhart, E. Abrutyn, R. Watson, R.K. Root, J. Egert Community-acquired *Acinetobacter calcoaceticus* var *anitratus* pneumonia *JAMA*, 238 (1977), pp. 1516–1518
39. L.G. Cordes, E.W. Brink, P.J. Checko, A. Lentnek, R.W. Lyons, P.S. Hayes, *et al.* A cluster of *Acinetobacter* pneumonia in foundry workers
40. Chen MZ, Hsueh PR, Lee LN, Yu CJ, Yang PC, Luh KT. Severe community-acquired pneumonia due to *Acinetobacter baumannii*. *Chest*. 2001;120:1072---7
41. Alvarez-Mann R. et al (2014) Epidemiology and treatment of multi-drug resistant *Acinetobacter baumannii*. *Current treatment options in infectious diseases*. 6: 409-424;
42. Sader et al (2014) Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009–2012. *International Journal of Antimicrobial Agents*. 43(4) 328-34
43. Weinstein RA et al. Overview of Nosocomial Infections Caused by Gram-Negative Bacilli. *Clin Infect Dis.* (2005) 41 (6) 848-854
44. Alvarez-Mann R. et al (2014) Epidemiology and treatment of multi-drug resistant *Acinetobacter baumannii*. *Current treatment options in infectious diseases*. 6: 409-424
45. Vincent J-L *et al* (2009) The Extended Prevalence of Infection in the ICU Study: EPIC II. Available at https://ddd.uab.cat/pub/artpub/2009/67882/PREI2010_jamav302n21.pdf. Accessed July 2016
46. De Francesco et al. Prevalence of multidrug-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa* in an Italian hospital. *Journal of Infection and Public Health*. June 2013. Vol 6 179-185
47. Dent LL et al. Multidrug resistant *Acinetobacter baumannii*: a descriptive study in a city hospital. *BMC infectious diseases*. 2010 10:196
48. Sukanya S et al. Prevalence of multidrug resistant *Acinetobacter baumannii* in clinical samples in a tertiary care hospital. *Int J Infect Control*. 2014
49. Maragakis LL et al. Incidence and prevalence of MDR *Acinetobacter* using targeted surveillance cultures. *JAMA*. 2008;299(21):2513-2514
50. Almomani B et al. Multidrug resistant *Acinetobacter baumannii* in ventilator associated pneumonia: Prevalence and predictors of mortality. *European Respiratory Journal* 2014 44: P2071
51. Agodi et al. Antibiotic trends of *Klebsiella pneumoniae* and *Acinetobacter baumannii* resistance indicators in an intensive care unit of Southern Italy, 2008–2013. *Antimicrobial Resistance and Infection Control* 2015 4:43
52. Perez F et al. Global challenge of Multidrug-Resistant *Acinetobacter baumannii*. *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*, Oct. 2007, p. 3471–3484
53. Siau H et al. *Acinetobacter* bacteremia in Hong Kong: prospective study a review. *Clin Inf Dis* 1999;28: 26-30
54. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin. Infect. Dis.* 39:309-317
55. Inchai J et al. Prognostic factors associated with mortality of drug-resistant *Acinetobacter baumannii* ventilator-associated pneumonia. *Journal of Intensive Care* 2015
56. Agodi et al. Antibiotic trends of *Klebsiella pneumoniae* and *Acinetobacter baumannii* resistance indicators in an intensive care unit of Southern Italy, 2008–2013. *Antimicrobial Resistance and Infection Control* 2015 4:43
57. *Antimicrobial Resistance and Infection Control* 2015 4:43
58. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2013.
59. Joly-Guillou ML. Clinical impact and pathogenicity of *Acinetobacter*. *Clin Microbiol Infect* 2005; 11: 868–873

60. Reddy T *et al* (2010) Trends in Antimicrobial Resistance of *Acinetobacter baumannii* Isolates from a Metropolitan Detroit Health System. *Antimicrob Agents Chemother.* 2010 May; 54(5): 2235–2238.
61. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. *Clin Infect Dis.* 2005;41:848–54
62. Lee *at al* (2010) Economic Impact of *Acinetobacter baumannii* Infection in the Intensive Care Unit. *Infect Control Hosp Epidemiol.* 2010 Oct; 31(10): 1087–1089
63. Hidron AI, Edwards JR, Patel J, *et al.* Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. *Infect Control Hosp Epidemiol.* 2008;29(11):996–1011
64. Wilson SJ, Knipe CJ, ZiegerMJ, Gabehart KM, Goodman JE, *et al.* (2004) Direct costs of multidrug-resistant *Acinetobacter baumannii* in the burn unit of a public teaching hospital. *Am J Infection Control* 32: 342-344.
65. Young LS, Sabel AL, Price CS(2007) Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant *Acinetobacter baumannii* infection in a surgical intensive care unit. *Infect Control HospEpidemiol*28: 1247-1254.
66. UN General Assembly. September 2016. World Health Leaders Agree on Action to Combat Antimicrobial Resistance, Warning of Nearly 10 Million Deaths Annually If Left Unchecked Available at: <https://www.un.org/press/en/2016/ga11825.doc.htm>. Accessed September 2016
67. World Health Organization. 27th February 2017. WHO publishes list of bacteria for which new antibiotics are urgently needed. Available at: <http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/> Accessed March 2017
68. Geller BL *et al.* Gene-Silencing Antisense Oligomers Inhibit *Acinetobacter* Growth In Vitro and In Vivo. *J Infect Dis.* 2013 Nov 15; 208(10): 1553–1560
69. Viertel TM *et al.* Viruses versus bacteria—novel approaches to phage therapy as a tool against multidrug-resistant pathogens. *J Antimicrobe. Chemother* (2014)
70. Actis LA. Insight into innovative approaches to battle *Acinetobacter baumannii* nfection therapy struggles. *Virulence.* 2010 Jan-Feb; 1(1); 6-7
71. Singh R *et al* (2016) Immunoprotective Efficacy of *Acinetobacter baumannii* Outer Membrane Protein, FliF, Predicted *In silico* as a Potential Vaccine Candidate. *Front. Microbiol.*, 12 February 2016 | <http://dx.doi.org/10.3389/fmicb.2016.00158>;
72. Chiang M-H *et al* (2015) Identification of novel vaccine candidates against *Acinetobacter baumannii* using reverse vaccinology. *Human Vaccines & Immunotherapeutics*, Volume 11, Issue 4
73. Pizza, M., Scarlato, V., Masignani, V., Giuliani, M. M., Aricò, B., Comanducci, M., *et al.* (2000). Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. *Science* 287, 1816–1820. doi: 10.1126/science.287.5459.1816
74. Garcia-Quintanilla M *et al* (2013) First steps towards a vaccine against *Acinetobacter baumannii*. [Curr Pharm Biotechnol.](#) 14(10):897-902;
75. Moriel D *et al* (2013) Identification of Novel Vaccine Candidates against Multidrug-Resistant *Acinetobacter baumannii*. *PLoS ONE* 8(10): e77631. doi:10.1371/journal.pone.0077631
76. ALOPEXX company website. Available at: <http://www.alopexx.com/company/vaccine/>. Accessed August 2016
77. Vaxdyn company website. Available at: <http://vaxdyn.com/index.php/products/pipeline>. Accessed August 2016
78. Skurnik D *et al.* The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG. *Expert Review of Vaccines.* 2016
79. Perez F & Bonomo R (2014) Vaccines for *Acinetobacter baumannii*: Thinking “out of the box”. *Vaccine.* 2014 May 7; 32(22): 2537–2539.
80. Lim WS *et al.* Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax* 2003;58:377–382
81. **VacZine Analytics. MarketVIEW:** *Pseudomonas aeruginosa* vaccines (CAT No: VAMV010), published January 2011
82. **VacZine Analytics. MarketVIEW:** *Staphylococcus aureus* vaccines (CAT No: VAMV002), published April 2012
83. Wunsch H *et al.* ICU Occupancy and mechanical ventilator use in the United States. *Crit Care Med.* 2013 Dec; 41(12): 10.1097/CCM.0b013e318298a139
84. Mullins PM *et al.* National Growth in Intensive Care Unit Admissions From ED in the US 2002-2009. *Acad Emer Med.* Vol 20, Issue 5, May 2013 Pages 479-486

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009